Prelude Therapeutics, Inc. (PRLD)

Over the past six months, Prelude Therapeutics' stock has experienced several notable events. In November 2025, the company reported its Q3 financial results with shares gaining 8.9% and announced pausing the clinical development of its SMARCA2 degrader program, leading to a stock decrease of 40.20%. An exclusive option agreement was announced with Incyte for Prelude's mutant selective JAK2V617F JH2 inhibitor program. In August 2025, Prelude reported Q2 earnings with shares increasing by 4.2%. In May 2025, Q1 earnings were reported, resulting in a 4.0% decrease in stock price. In March 2025, Q4 2024 earnings were announced, leading to a 9.0% drop in stock price. Changes to its Chief Financial Officer were announced in April 2025. The company was dropped from the Russell 2000 Growth Index and Russell 3000E Value Index in June 2025. The stock price has increased by 17.67% in the past month but decreased by 29.64% over the last 12 months.

As a clinical-stage biotechnology company, Prelude Therapeutics, Inc. does not currently have commercialized products or services on the market, so there is no established demand seasonality. Demand for its future products will be driven by clinical trial success, regulatory approvals, and the prevalence of the specific cancer types they aim to treat.

Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on discovering and developing novel cancer medicines. The company operates in the Healthcare sector, specifically in the Biotechnology and Pharmaceutical Products industry, focusing on small molecule therapies, targeted protein degraders, and next-generation degrader antibody conjugates. Its pipeline includes clinical development candidates such as PRT1419, PRT2527, PRT3645, PRT3789, PRT7732, KAT6A degraders, and Mutant selective JAK2V617F JH2 inhibitors.

Prelude Therapeutics, Inc. is headquartered in Wilmington, Delaware, United States. Its primary operations are centered around research and development, with no explicit information available regarding a broader international commercial or operational footprint for its products.

In the past year, Prelude Therapeutics has received a consensus "Hold" rating from Wall Street equities research analysts, with an average rating score of 2.33. MarketBeat evaluated Prelude Therapeutics as scoring higher than 48% of companies in the medical sector. Events affecting the company's reputation include pausing the clinical development of its SMARCA2 degrader program, being downgraded by Morgan Stanley, and receiving FDA clearance to start a Phase 1 trial for a cancer candidate.

Prelude Therapeutics Incorporated has 72 institutional owners and shareholders, holding a total of 27,831,291 shares. Major institutional owners include Orbimed Advisors Llc, Baker Bros. Advisors Lp, Vanguard Group Inc, Millennium Management Llc, Price T Rowe Associates Inc /Md/, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, PRHSX - T. Rowe Price Health Sciences Fund, Inc., Renaissance Technologies Llc, Acadian Asset Management Llc, and Morgan Stanley. Retail investors hold the largest share of the company at 40%, while hedge funds own 21%. Baker Bros. Advisors LP is the largest single shareholder with 21% of outstanding shares, and CEO Krishna Vaddi holds 3.8% of the shares. The top four shareholders collectively control over half of the company.